OncoSec Announces Acceptance of Late Breaking Abstract at Upcoming Society for Immunotherapy of Cancer (SITC) Annual Meeting 2017
PR Newswire PR NewswireOctober 11, 2017 Additional abstract highlighting preclinical data from OncoSec's novel multi-gene expression platform
SAN DIEGO, Oct. 11, 2017 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec") (ONCS), a company developing DNA-based intratumoral cancer immunotherapies, will present updated clinical data from its phase 2 Investigator Sponsored Trial assessing the combination of OncoSec's investigational therapy, ImmunoPulse® IL-12 (intratumoral pIL-12 [tavokinogene telseplasmid or "tavo"] with electroporation), and the approved anti-PD-1 therapy pembrolizumab, in patients with unresectable metastatic melanoma. The late-breaking poster presentation will occur at the upcoming Society for Immunotherapy of Cancer ("SITC") 32nd Annual Meeting to be held on November 8-12, 2017, in National Harbor, MD. In addition, OncoSec will present preclinical data from its novel multi-gene expression platform termed PIIM (Polycistronic Interleukin-12 Immune Modulator) as a poster presentation at the same meeting.
"We are pleased that the Society for Immunotherapy of Cancer will highlight updated clinical data from our phase 2 study that led us to initiate our global, open-label, registration directed phase 2b clinical trial, PISCES/KEYNOTE-695, which will evaluate the combination of ImmunoPulse IL-12 and pembrolizumab in metastatic melanoma patients who are progressing or have progressed on anti-PD-1," said Punit Dhillon, CEO and President at OncoSec. "We remain committed to excelling in scientific innovation and clinical development and look forward to sharing data from our recently initiated study in mid-2018."
The late-breaking poster presentation details are as follows:
Title: Clinical and biomarker analyses of a phase II study of intratumoral tavokinogene telseplasmid (pIL-12) plus pembrolizumab in stage III/IV melanoma patients predicted to not respond to anti-PD-1
Poster Number: P524
Lead Author: Alain Algazi, MD, Associate Professor, Department of Medicine (Hematology/Oncology), UCSF
Date and Time: Saturday, November 11th, 12:30-2:00 p.m. and 6:30-8:00 p.m.
Location: Gaylord National Resort & Convention Center
Title: Intratumoral administration of a multigene construct by electroporation can effectively modulate anti-tumor response in a murine B16.F10 model
Poster Number: P403
Lead Author: Shawna Shirley, Ph.D., Senior Scientist, OncoSec
Session Title: Oncolytic Viruses and Intratumoral Therapies
Date and Time: Friday, November 10th, 12:30-2:00 p.m. and 6:30-8:00 p.m.
Location: Gaylord National Resort & Convention Center
Per SITC guidelines, abstracts are embargoed until 8:00 a.m. EST on November 7, 2017. To view abstracts, please visit the SITC website at https://www.sitcancer.org/2017/abstracts/info.
ImmunoPulse® is a registered trademark of OncoSec Medical Incorporated, San Diego, CA, USA.
About the SITC Annual Meeting The Society for Immunotherapy of Cancer (SITC) is a non-profit medical professional society of influential scientists, academicians, researchers, clinicians, government representatives, and industry leaders from around the world dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy. Currently, SITC has nearly 1,600 members representing 17 medical specialties and are engaged in research and treatment of at least a dozen types of cancer. The 32nd SITC Annual Meeting & Associated Programs will take place November 8-12, 2017 at the Gaylord National Hotel & Convention Center in National Harbor, MD. For more information, please go to www.sitcancer.org/2017.
About PISCES (Anti-PD-1 IL-12 Stage III/IV Combination Electroporation Study) PISCES is a global, multicenter phase 2b, open-label trial of intratumoral plasma encoded IL-12 (tavokinogene telseplasmid or "tavo") delivered by electroporation in combination with intravenous pembrolizumab in patients with stage III/IV melanoma who have progressed or are progressing on either pembrolizumab or nivolumab treatment. The Simon 2-stage study of intratumoral tavo plus electroporation in combination with pembrolizumab will enroll approximately 48 patients with histological diagnosis of melanoma with progressive locally advanced or metastatic disease defined as Stage III or Stage IV. The primary endpoint will be the Best Overall Response Rate (BORR).
